Table 2.
Group 1. demographics of participant groups at the first appointment, showing the mean with SD in brackets and range below
| HD controls (non-antidopaminergic takers) (n=466) |
HD antidopaminergic takers (n=466) |
|
| Number of visits | 3 (1) 2–6 |
3.1 (1) 2–6 |
| Gender (m:f) | 234:232 | 267:200 |
| ISCED (educational level) |
3.6 (1.2) 1–6 |
3.5 (1.2) 1–6 |
| Age (years) |
54.6 (9.7) 26–79 |
54.4 (9.2) 26–79 |
| CAG repeat length | 43 (2.1) 40–55 |
43.1 (2.1) 40–55 |
| DBS | 394.4 (55) 180–573.5 |
397 (55.2) 180–573.5 |
| TFC score | 9.9 (2.4) 3–13 |
9.3 (2.5) 3–13 |
| Time since diagnosis (years) |
3.4 (3.7) 0–22 |
3.8 (3.7) 0–22 |
| Total motor score UHDRS Max score 124 |
28.1 (14.6) 0–81 |
33.8* (15.5) 0–85 |
| Total chorea score UHDRS Max score 28 |
8.2 (4.5) 0–26 |
9.3* (5.2) 0–28 |
| Irritability (PBA) Max score 32 |
2.5 (3.9) 0–25 |
3.5* (5.1) 0–28 |
| Depression (PBA) Max score 48 |
4.3 (5.8) 0–36 |
5.7* (6.7) 0–36 |
| Apathy (PBA) Max score 16 |
2.2 (3.4) 0–16 |
3.7* (4.4) 0–16 |
| MMSE Max score 30 |
26.7 (2.7) 14–30 |
25.7* (3.3) 11–30 |
| Composite cognitive z-score | 1.3 (5.3) −21.7 to 18.9 |
|
ISCED, The International Standard Classification of Education; CAG, cytosine-adenine-guanine; MMSE, Mini-Mental State Examination.
*Indicates a significant difference (p<0.001) when compared with the control non-antidopaminergic medication group.
DBS, disease burden score; HD, Huntington’s disease; PBA, problems behavioural assessment; TFC, total functional capacity; UHDRS, Unified Huntington Disease Rating Scale.